10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

LAR Rabbit pAb

LAR Rabbit pAb
Catalog # AP54534

Product Information

Primary Accession	P10586
Reactivity	Human
Predicted	Rat, Dog, Mouse, Rabbit, Horse, Sheep
Host	Rabbit
Clonality	Polyclonal
Calculated MW	212879
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human PTPRF
Epitope Specificity	30-100/1907
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SUBCELLULAR LOCATION	Membrane; Single-pass type I membrane protein.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and two tandem intracytoplasmic catalytic domains, and thus represents a receptor-type PTP. The extracellular region contains three Ig-like domains, and nine non-Ig like domains similar to that of neural-cell adhesion molecule. This PTP was shown to function in the regulation of epithelial cell-cell contacts at adherents junctions, as well as in the control of beta-catenin signaling. An increased expression level of this protein was found in the insulin-responsive tissue of obese, insulin-resistant individuals, and may contribute to the pathogenesis of insulin resistance. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008]

Additional Information

Gene ID	5792
Other Names	Receptor-type tyrosine-protein phosphatase F, 3.1.3.48, Leukocyte common antigen related, LAR, PTPRF, LAR
Dilution	Flow-Cyt=1 □g/Test
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When

reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.


Protein Information

Name	PTPRF
Synonyms	LAR
Function	Possible cell adhesion receptor. It possesses an intrinsic protein tyrosine phosphatase activity (PTPase) and dephosphorylates EPHA2 regulating its activity.
Cellular Location	Membrane; Single-pass type I membrane protein.


Background

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Images




Blank control:MCF7.
Primary Antibody (green line): Rabbit Anti-LAR antibody (AP54534)
Dilution: 2 µg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody : Goat anti-rabbit IgG-AF488
Dilution: 1 µg /test.
Protocol
The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.



Blank control(blue): Hela Cells(fixed with 2% paraformaldehyde (10 min)).
Primary Antibody: Rabbit Anti-LAR/AF488 Conjugated antibody (AP54534-AF488), Dilution: 1 µg in 100 µL 1X PBS containing 0.5% BSA;
Isotype Control Antibody: Rabbit IgG/AF488(orange) ,used under the same conditions.

Blank control:MCF7.
Primary Antibody (green line): Rabbit Anti-LAR antibody (AP54534)
Dilution: 2 µg /10^6 cells;



Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody : Goat anti-rabbit IgG-AF488
Dilution: 1 µg /test.
Protocol
The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.